Effect of intravenous lidocaine and intravenous magnesium sulfate in reduction of myoclonic movements

Comparison of intravenous lidocaine and intravenous magnesium sulfate in reduction of myoclonic movements fallowing etomidate in orthopedic surgery

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017062134674N1

Enrollment

117

Registered

2017-08-13

Start date

2017-07-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myoclonus. Drug-induced myoclonus

Interventions

Intervention 1: Intervention group 1: magnesium sulfate 5 mg/kg single dose. Intervention 2: Intervention group 2: lidocaine 2% 1 mg/kg single dose. Intervention 3: Control group: Distilled water 5 cc

Treatment - Drugs

Placebo

Intervention group 1: magnesium sulfate 5 mg/kg single dose

Intervention group 2: lidocaine 2% 1 mg/kg single dose

Control group: Distilled water 5 cc

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients who candidate for orthopedic surgery Exclusion criteria: ASA anesthesia risk class 3 and higher; emergency surgery; history of opium, anticonvulsant and sedative drugs; patients with Parkinson; contraindication for lidocaine and magnesium sulfate

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Myoclonus. Timepoint: Within 90 seconds after injection of the main drug for induction of anesthesia. Method of measurement: Observation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMobina Hakimi Nia

Shahroud University of Medical Sciences

mobina.hakiminia@yahoo.com+98 23 3239 4499

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026